Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.soard.2016.08.494 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk Factors for Acute Pancreatitis Following Intragastric Balloon Insertion: A 7-Year Retrospective Cohort Study.
Obes Surg
January 2025
Hamad Medical Corporation, Doha, Qatar.
Background: Acute pancreatitis (AP) is a rare but serious complication of intragastric balloon (IGB) therapy. Despite the popularity of IGBs for weight loss, the incidence and risk factors of AP post-IGB insertion are not well understood. This study aimed to identify potential predictors and risk factors of AP in IGB patients.
View Article and Find Full Text PDFClinical Outcomes in Patients Undergoing Sequential Intragastric Balloon (IGB) Treatment for Super Obesity: A Single Centre Retrospective Analysis.
J Metab Bariatr Surg
December 2024
Department of General Surgery, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield, Yorkshire, United Kingdom.
Purpose: We aimed to assess outcomes in patients undergoing sequential intragastric balloon (IGB) treatment for obesity.
Materials And Methods: Consecutive patients who underwent treatment between May 2014 and February 2023 were identified. We recorded outcomes including: weight at 3-monthly intervals, progression to definitive bariatric procedure and morbidity.
The Effect of Tacrine on Functional Response of the Lower Oesophageal Sphincter Assessed by Endoscopic Luminal Impedance Planimetry in Experimental Pigs.
Pharmaceuticals (Basel)
November 2024
Biomedical Research Centre, University Hospital Hradec Kralove, 500 05 Hradec Kralove, Czech Republic.
Tacrine is a centrally active non-competitive reversible acetylcholinesterase inhibitor. It also exerts antagonising activity against -methyl-D-aspartate receptors. Tacrine was approved for the treatment of Alzheimer's disease in 1993, but was withdrawn from clinical use in 2013 because of its hepatotoxicity and gastrointestinal side effects.
View Article and Find Full Text PDFIntragastric balloon adverse events: a comprehensive MAUDE database review.
Proc (Bayl Univ Med Cent)
October 2024
Department of Gastroenterology and Hepatology, The University of Florida College of Medicine - Jacksonville, Jacksonville, Florida, USA.
Background: Endoscopic bariatric interventions are viable alternatives to traditional weight loss surgeries for patients with a body mass index between 30 and 40 kg/m. While studies have explored the impact of intragastric balloons on obesity and weight reduction, comprehensive data on real-world device-related complications and failures are limited. This study aimed to investigate mechanical failures leading to patient adverse events reported to the US Food and Drug Administration.
View Article and Find Full Text PDFBurst that Bubble. Gastric Perforation from an Ingested Intragastric Balloon: A Case Report.
Clin Pract Cases Emerg Med
November 2024
Texas Tech University Health Sciences Center at El Paso, Department of Emergency Medicine, El Paso, Texas.
Introduction: More than 40% of Americans are considered obese, resulting in annual healthcare costs estimated at $173 billion., Various interventions exist to address obesity including lifestyle modification, medications, and several surgical options. A novel ingestible intragastric balloon that self-deflates and is excreted approximately four months post-ingestion is being used in other countries such as Australia, Mexico, and several European countries.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!